Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px
Document › Details

Orchard Therapeutics Ltd.. (2/13/18). "Press Release: Orchard Therapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference". London.

Organisations Organisation Orchard Therapeutics Ltd.
  Group Orchard Therapeutics (Group)
  Organisation 2 RBC Capital Markets, LLC
Products Product RBC Capital Markets Global Healthcare Conference 2018 New York
  Product 2 gene therapy
Index terms Index term Orchard Therapeutics–RBC Capital Markets: investor conference, 201802 supply service Orchard at RBC Capital Markets Global Healthcare Conference
  Index term 2 Orchard Therapeutics–LifeSci: public relations, 201712 service existent by LifeSci Public Relations
Persons Person Rothera, Mark (Orchard Therapeutics 201708– CEO before PTC Therapeutics + Aegerion + Shire Human Genetic Therapies)
  Person 2 Blum, Allison (LifeSci Public Relations 201712)
     


Orchard Therapeutics, a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, today announced that Mark Rothera, Orchard’s president and chief executive officer, will present at the RBC Capital Markets 2018 Global Healthcare Conference in New York City on Wednesday, February 21, 2018 at 10:30 a.m. ET.


About Orchard Therapeutics

Orchard Therapeutics is a privately held clinical-stage biotechnology company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies. Orchard, based in the UK and US, has partnered with world leading institutions in gene therapy, including University College London, Great Ormond Street Hospital, the University of Manchester and Central Manchester University Hospitals, the University of California Los Angeles and Boston Children’s Hospital. Orchard’s growing pipeline of autologous ex vivo lentiviral gene therapy programs for rare immune deficiencies and metabolic disorders includes late clinical stage programs that have already demonstrated the transformative power of gene therapy on patients’ lives. In 2016 the company was named a Fierce 15 Company by Fierce Biotech and was awarded a $19 million grant from the California Institute of Regenerative Medicine (CIRM) to advance their autologous ex vivo lentiviral gene therapy in ADA-SCID. In 2017, Orchard raised $110 million in a Series B round of funding to further develop its pipeline in parallel with enhancing manufacturing capabilities.


Contacts

Corporate contact
Nicolas Koebel
Orchard Therapeutics
+44 (0) 203 384 6700
Nicolas.koebel@orchard-tx.com

Media contact
Allison Blum, Ph.D.
LifeSci Public Relations
+1 516 655 0842
Allison@lifescipublicrelations.com

   
Record changed: 2018-05-07

Advertisement

Picture [iito] – Putting Information into Context 600x102px

More documents for Orchard Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 600x60px




» top